INTERNATIONAL STEM CELL CORPORATION Financials International Stem Cell Corporation
Equities
ISCO
US4603782016
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.09 USD | 0.00% |
|
-7.22% | +45.16% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 10.61 | 4.369 | 2.789 | 3.786 | 1.441 | 0.4963 |
| Enterprise Value (EV) 1 | 11.58 | 7.34 | 6.424 | 7.687 | 4.974 | 3.086 |
| P/E ratio | -4.59 x | -1.02 x | -1.02 x | -4.12 x | -4.35 x | -3.79 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.96 x | 0.46 x | 0.39 x | 0.53 x | 0.18 x | 0.06 x |
| EV / Revenue | 1.04 x | 0.77 x | 0.9 x | 1.07 x | 0.61 x | 0.4 x |
| EV / EBITDA | -4.52 x | -1.88 x | -2.57 x | -5.46 x | 142 x | -6.58 x |
| EV / FCF | -4.84 x | -2.89 x | 11.5 x | -10 x | 18.6 x | 8.11 x |
| FCF Yield | -20.6% | -34.6% | 8.67% | -9.97% | 5.37% | 12.3% |
| Price to Book | 4.19 x | -1.51 x | -0.64 x | -0.82 x | -0.32 x | -0.12 x |
| Nbr of stocks (in thousands) | 6,934 | 7,533 | 7,539 | 8,004 | 8,004 | 8,004 |
| Reference price 2 | 1.530 | 0.5800 | 0.3700 | 0.4730 | 0.1800 | 0.0620 |
| Announcement Date | 15/04/19 | 01/06/20 | 30/03/21 | 29/03/22 | 30/03/23 | 28/03/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 11.09 | 9.472 | 7.128 | 7.176 | 8.18 | 7.789 |
| EBITDA 1 | -2.559 | -3.903 | -2.5 | -1.409 | 0.035 | -0.469 |
| EBIT 1 | -2.867 | -4.188 | -2.753 | -1.671 | -0.183 | -0.663 |
| Operating Margin | -25.85% | -44.21% | -38.62% | -23.29% | -2.24% | -8.51% |
| Earnings before Tax (EBT) 1 | -2.131 | -4.265 | -2.724 | -0.899 | -0.331 | -0.131 |
| Net income 1 | -2.131 | -4.265 | -2.724 | -0.899 | -0.331 | -0.131 |
| Net margin | -19.22% | -45.03% | -38.22% | -12.53% | -4.05% | -1.68% |
| EPS 2 | -0.3336 | -0.5677 | -0.3613 | -0.1148 | -0.0414 | -0.0164 |
| Free Cash Flow 1 | -2.391 | -2.543 | 0.5568 | -0.7664 | 0.2672 | 0.3808 |
| FCF margin | -21.56% | -26.84% | 7.81% | -10.68% | 3.27% | 4.89% |
| FCF Conversion (EBITDA) | - | - | - | - | 763.57% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 15/04/19 | 01/06/20 | 30/03/21 | 29/03/22 | 30/03/23 | 28/03/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.97 | 2.97 | 3.64 | 3.9 | 3.53 | 2.59 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.3791 x | -0.7612 x | -1.454 x | -2.769 x | 100.9 x | -5.522 x |
| Free Cash Flow 1 | -2.39 | -2.54 | 0.56 | -0.77 | 0.27 | 0.38 |
| ROE (net income / shareholders' equity) | -92.6% | -216% | -395% | 560% | 130% | 245% |
| ROA (Net income/ Total Assets) | -24.4% | -36.3% | -28.9% | -20.4% | -2.27% | -7.87% |
| Assets 1 | 8.717 | 11.74 | 9.425 | 4.404 | 14.59 | 1.664 |
| Book Value Per Share 2 | 0.3700 | -0.3800 | -0.5800 | -0.5700 | -0.5700 | -0.5200 |
| Cash Flow per Share 2 | 0.1600 | 0.0600 | 0.0900 | 0.0200 | 0.0900 | 0.2000 |
| Capex 1 | 0.19 | 0.16 | 0.03 | 0.02 | 0 | 0.08 |
| Capex / Sales | 1.67% | 1.73% | 0.39% | 0.32% | 0.01% | 1.03% |
| Announcement Date | 15/04/19 | 01/06/20 | 30/03/21 | 29/03/22 | 30/03/23 | 28/03/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +45.16% | 7L | |
| +33.63% | 5.08TCr | |
| -0.09% | 4.28TCr | |
| +49.62% | 4.2TCr | |
| -4.96% | 2.95TCr | |
| +11.18% | 2.61TCr | |
| -21.95% | 1.91TCr | |
| +8.61% | 1.31TCr | |
| +28.31% | 1.22TCr | |
| +24.73% | 1.21TCr |
- Stock Market
- Equities
- ISCO Stock
- Financials International Stem Cell Corporation
